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Abstract
Background: It has been shown that proteins fused to ubiquitin undergo greater expression in E.
coli and are easier to purify and renaturate than nonhybrid foreign proteins. However, there is no
commercial source of large quantities of specific deubiquitinating proteases. This is the reason why
hybrid proteins containing ubiquitin at their N-end cannot be used in large scale biotechnological
processes.
Results and Conclusion: We have described the synthesis of the yeast deubiquination enzyme
UBP1 muteins in E. coli. We have shown that an efficient overproduction of the enzyme in E. coli
may be achieved after the introduction of several changes in the nucleotide sequence encoding
UBP1. One of the conditions of an effective synthesis of the UBP1 muteins is the removal of the 5'-
end sequence encoding the transmembrane region of the enzyme. The obtained variants of the
enzyme may be successfully used for processing large amounts of hybrid proteins comprising
ubiquitin or tagged ubiquitin at their N-ends.
Background
Ubiquitin is composed of 76 amino-acid residues with a
total molecular mass of 8.6 kDa. This protein is an ele-
ment of the universal protein modification in eukaryots
called ubiquitination, a phenomenon which does not
occur in bacteria. In spite of that, it has been shown that
proteins fused to ubiquitin undergo greater expression in
E. coli and are easier to purify and renaturate than nonhy-
brid foreign proteins [1]. However, to take advantage of
these properties of hybrid proteins in technological proc-
esses, large amounts of proteases for cleaving specifically
ubiquitin from those proteins are necessary. Protease
UBP1, an enzyme found in the yeast Saccharomyces cerevi-
siae, is a candidate for becoming such a tool. The enzyme
was described in 1991 [2] and is the subject of a patent
application [3]. UBP1 is a cysteine protease which cleaves
ubiquitin from protein fused to its C-end. Its activity and
culture conditions in E. coli have been described [2], but
the problem of a larger and more efficient production of
the enzyme remains unsolved and for that reason techni-
cal applications of the inventions mentioned in [3] have
not been possible.
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The aim of this work was to obtain an expression system
for an efficient synthesis of UBP1 protease variants that
would be useful in industrial processes.
Results and Discussion
We were not able to obtain an efficient expression of the
full coding sequence of UBP1. This is in agreement with
the results of Tobias and Varshavsky [2], who were able to
detect UBP1 in E. coli only after an immunoblot analysis.
A possible reason for this situation might be the presence
of a transmembrane region in the N-end part of the pro-
tein, which was discovered after a computer analysis using
the TMHMM v. 2.0 software package (CBS, Denmark) [4].
The region encompasses amino-acids 34–51 (Figure 1).
Because of that, we decided to prepare truncated variants
of the sequences encoding UBP1 without the transme-
brane region. Using the PCR technique, two shortened
genes were prepared without the 5' parts of the UBP1 cod-
ing region. Proteins encoded by these variants of the gene
are shorter by 54 and 98 amino-acids (Figure 1). Expres-
sion of these analogues of the UBP1 gene inserted into
pT7RS derivatives was analyzed. In addition, the influence
of one mutation, named Q754L, within the UBP1 gene,
which happened during PCR amplification, on the expres-
sion level was investigated (Figure 1A).
Expression of the UBP1 variants in E. coli
The obtained plasmids with the hybrid genes encoding
the analogues: UBI::UBPD,  UBI::UBPDQL, and
UBI::UBPD2QL were used to transform the E. coli BLD21
strain. In general, several expression host strains and dif-
ferent culture conditions were examined (results not
shown) in our mini-induction screening experiments to
optimize recombinant protein expression. The cultures
were grown at 37°C and 25°C until OD600 nm reached
0.5–1.8 and 1 ml samples were removed from each cul-
ture and saved as controls. Then, isopropyl β -D-thiogalac-
toside was added to the cultures at the desired
concentration of 0.5–1.0 mM. Aliquots of cultures were
taken 30, 60, 90, 120 and 150 min. post-induction (Figure
2). Cell density in these samples was measured to monitor
the protein induction process and to normalize total pro-
teins in E. coli after cell lysis in the 2xSDS sample buffer.
The expression level (Figure 3) of the recombinant pro-
teins was determined by a densitometric analysis of the
electrophoretic pattern. The protein level was equal to 7.2
% and 9.8 % of the proteins visible in lines 2 and 5 (Figure
3) for UBPDQL and UBPD2QL, respectively. The results
shown in Fig. 4 and 5 indicate that the fusions of ubiqui-
tin with UBP1 analogues are active proteases during cell
culture because an intensive band of ubiquitin is visible
on SDS gels after electrophoresis of E. coli lysates.
The main factors influencing the expression level of UBP1
analogues and growth rate of bacteria are: the presence or
absence of the Q754L mutation (Figure 5) and lack of the
transmembrane region at the N-end of UBP1 (Figure 3).
The lack of Q754L mutation in the UBP1 analogue gene
makes an efficient production of the enzyme impossible
because of a very slow culture growth rate and a low level
of protease expression (results not shown). Apart from
that we have shown that the removal of the transmem-
brane region leads to a significant reduction in growth
time and an increase in the expression level (Figure 3).
The period of time to reach OD600 = 1 for UBPD, UBPDQL
and UBPD2QL was 48, 12 and 9 h, respectively. It appears
also that the bacteria containing the vector with the
shorter gene of the UBP1 analogue encoding UBPD2QL
produce the highest amount of the recombinant protease
(Figure 3 and 4). It was also established that the presence
of the proper codons in the gene used for expression addi-
tionally shortened the period of time necessary to reach
OD600 = 1 (results not shown). All things considered, the
best expression system consists of the gene variant with
the Q754L mutation, larger deletion of the N-end encod-
ing sequence and proper codon usage. The best results
were obtained when the bacteria culture was carried out at
25°C, the induction with IPTG begun when OD had
reached 1 and when the culture time after induction was
2h (Figure 2).
Purification of the recombinant UBPD2QLHisx6 protease 
and fusion proteins of the type 6xHisUBI::protein
For purification, the cells from 0.5 litre culture after a 2-
hour induction at 25°C in the presence of 1 mM IPTG
were harvested. The pellet was resuspended in 50 ml of
buffer A. All subsequent steps were performed at 4°C. The
cells were disrupted by sonication on ice and the insolu-
ble debris was removed by centrifugation for 25 min. at
11500 rpm. The cleared extract was chromatographed on
a Ni-NTA Superflow column, pre-equilibrated with 10
vol. of buffer A. After loading, the column was washed
with 5 vol. of buffer B and then the protease was eluted
twice with elution buffer C. Protein concentrations were
determined using the Bradford dye binding assay and
bovine serum albumin as the standard. Both analogues of
UBP1, UBPDQL and UBPD2QL, were purified in the
same manner. Digestion of the two substrates,
6xHisUBI::S and UBI::K, shows that the preparations of
the two different UBP1 analogues are active proteases, but
the activity of the shorter one (UBP1DC2) is higher (Fig-
ure 6). Stability of both the UBPDQL and UBPD2QL ana-
logues during long exposure to 37°C was also
investigated. It appeared that both enzymes were active
after 24 h incubation (results not shown).
We obtained 13.8 mg of purified UBPDQL and 20 mg of
purified UBPD2QL from 1 l of E. coli culture. The
amounts represent 6.3% and 7.4% of the total protein
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Nucleotide and amino-acid sequences of the yeast UBP1 gene and UBP1 protease [2] Figure 1
Nucleotide and amino-acid sequences of the yeast UBP1 gene and UBP1 protease [2]. A) The nucleotide residues 
are numbered on the left, and amino acid residues are numbered on the right of the figure. The underlined AGA or AGG 
arginine and TTA leucine codons were changed for CGC or CGT and CTG triplets, respectively. The CAG triplet (shown in 
bold) at positions 2260–2262 was changed to CTG one (Q754L mutation). The amino-acids forming active centre is shown in 
italics [4]. For the construction of UBI::UBPDQL or UBI::UBPD2QL coding sequences the first 162 bp or 294 bp which were 
removed are overlined or underlined, respectively. The 3'part of the UBP1 gene (positions: 2074–2430) was used to construct 
the S protein, the truncated hybrid protein which was used to determine the UBP1 variants' activity. B) Schematic structure of 
UBI::UBP1 construction variants.   – ubiquitin,  – UBP1,   – 6xHis.
                      M    D    L    F    I    E    S    K    I    N    S    L    L    Q    F    L    F    G    S    R    Q    D    F    L    R    N    F    K    T      29
              1    ATGGATTTGTTTATTGAAAGCAAGATAAACAGTTTATTACAATTTTTATTTGGTTCCCGACAGGATTTTTTGAGAAATTTTAAAACT 
                      W    S    N    N    N    N    N    L    S    I    Y    L    L    I    F    G    I    V    V    F    F    Y    K    K    P    D    H    L    N      58
            88    TGGAGTAACAACAATAACAATCTATCGATTTATTTATTAATTTTTGGCATAGTAGTATTTTTTTATAAAAAACCAGACCATCTAAAC 
                      Y    I    V    E    S    V    S    E    M    T    T    N    F    R    N    N    N    S    L    S    R    W    L    P    R    S    K    F    T      87
          175    TACATTGTTGAGAGCGTTAGTGAAATGACAACAAACTTCAGAAATAATAATAGCCTTAGCCGTTGGTTGCCCAGAAGTAAGTTTACC 
                      H    L    D    E    E    I    L    K    R    G    G    F    I    A    G    L    V    N    D    G    N    T    C    F    M    N    S    V    L      116
          262    CACTTAGACGAAGAGATCTTGAAAAGAGGTGGTTTCATTGCTGGTTTAGTTAATGATGGTAACACTTGTTTTATGAACTCTGTTTTG 
                      Q    S    L    A    S    S    R    E    L    M    E    F    L    D    N    N    V    I    R    T    Y    E    E    I    E    Q    N    E    H      145
          349    CAATCATTGGCATCATCCAGAGAATTAATGGAGTTCTTGGACAATAATGTCATAAGGACCTATGAGGAGATAGAACAAAATGAACAC 
                      N    E    E    G    N    G    Q    E    S    A    Q    D    E    A    T    H    K    K    N    T    R    K    G    G    K    V    Y    G    K      174
          436    AATGAAGAAGGAAACGGGCAAGAATCTGCTCAAGATGAAGCCACTCATAAGAAAAACACTCGTAAGGGTGGCAAAGTTTATGGTAAG 
                      H    K    K    K    L    N    R    K    S    S    S    K    E    D    E    E    K    S    Q    E    P    D    I    T    F    S    V    A    L      203
          523    CATAAGAAGAAATTGAATAGGAAGTCAAGTTCGAAAGAAGACGAAGAAAAGAGCCAGGAGCCAGATATCACTTTCAGTGTCGCCTTA 
                      R    D    L    L    S    A    L    N    A    K    Y    Y    R    D    K    P    Y    F    K    T    N    S    L    L    K    A    M    S    K      232
          610    AGGGATCTACTTTCTGCCTTAAATGCGAAGTATTATCGGGATAAACCCTATTTCAAAACCAATAGTTTATTGAAAGCAATGTCCAAA 
                      S    P    R    K    N    I    L    L    G    Y    D    Q    E    D    A    Q    E    F    F    Q    N    I    L    A    E    L    E    S    N      261
          697    TCTCCAAGAAAAAATATTCTTCTTGGCTACGACCAAGAGGACGCGCAAGAATTCTTCCAGAACATACTAGCCGAGTTGGAAAGTAAC 
                      V    K    S    L    N    T    E    K    L    D    T    T    P    V    A    K    S    E    L    P    D    D    A    L    V    G    Q    L    N      290
          784    GTTAAATCATTGAATACTGAAAAACTAGATACCACTCCAGTTGCGAAATCAGAATTACCCGATGATGCTTTAGTAGGTCAACTTAAC 
                      L    G    E    V    G    T    V    Y    I    P    T    E    Q    I    D    P    N    S    I    L    H    D    K    S    I    Q    N    F    T      319
          871    CTTGGTGAAGTTGGCACTGTTTACATTCCAACTGAACAGATTGATCCTAACTCTATACTACATGACAAGTCCATTCAAAATTTCACA 
                      P    F    K    L    M    T    P    L    D    G    I    T    A    E    R    I    G    C    L    Q    C    G    E    N    G    G    I    R    Y      348
          958    CCTTTCAAACTAATGACTCCTTTAGATGGTATCACGGCAGAAAGAATTGGTTGTTTACAGTGTGGTGAGAACGGTGGCATAAGATAT 
                      S    V    F    S    G    L    S    L    N    L    P    N    E    N    I    G    S    T    L    K    L    S    Q    L    L    S    D    W    S      377
        1045    TCCGTATTTTCGGGATTAAGCTTAAATTTACCGAACGAGAATATTGGTTCCACTTTAAAATTATCTCAGTTATTAAGCGACTGGAGT 
                      K    P    E    I    I    E    G    V    E    C    N    R    C    A    L    T    A    A    H    S    H    L    F    G    Q    L    K    E    F      406
        1132    AAACCTGAAATCATCGAAGGCGTAGAATGTAACCGTTGTGCCCTCACAGCAGCGCACTCTCATTTATTTGGTCAGTTGAAAGAATTT 
                      E    K    K    P    E    G    S    I    P    E    K    P    I    N    A    V    K    D    R    V    H    Q    I    E    E    V    L    A    K      435
        1219    GAAAAAAAACCTGAGGGTTCGATCCCAGAAAAGCCAATTAACGCTGTAAAAGATAGGGTCCATCAAATCGAAGAAGTTCTTGCCAAA 
                      P    V    I    D    D    E    D    Y    K    K    L    H    T    A    N    M    V    R    K    C    S    K    S    K    Q    I    L    I    S      464
        1306    CCAGTTATTGACGATGAAGATTATAAGAAGTTGCATACAGCAAATATGGTACGTAAATGCTCTAAATCTAAGCAGATTTTAATATCA 
                      R    P    P    P    L    L    S    I    H    I    N    R    S    V    F    D    P    R    T    Y    M    I    R    K    N    N    S    K    V      493
        1393    AGACCTCCACCATTATTATCCATTCATATCAACAGATCCGTATTTGATCCAAGAACGTACATGATTAGAAAAAATAACTCGAAAGTA 
                      L    F    K    S    R    L    N    L    A    P    W    C    C    D    I    N    E    I    N    L    D    A    R    L    P    M    S    K    K      522
        1480    TTGTTTAAGTCAAGGTTGAATCTTGCCCCATGGTGTTGTGATATTAATGAAATCAATTTGGATGCTCGTTTGCCAATGTCAAAAAAG 
                      E    K    A    A    Q    Q    D    S    S    E    D    E    N    I    G    G    E    Y    Y    T    K    L    H    E    R    F    E    Q    E      551
        1567    GAAAAAGCTGCGCAACAAGATTCAAGTGAAGATGAAAACATTGGCGGTGAATACTATACGAAATTACATGAACGCTTCGAGCAGGAA 
                      F    E    D    S    E    E    E    K    E    Y    D    D    A    E    G    N    Y    A    S    H    Y    N    H    T    K    D    I    S    N      580
        1654    TTTGAAGACAGCGAGGAAGAAAAAGAATACGATGACGCAGAGGGGAACTATGCGTCTCATTACAATCATACCAAGGATATCAGTAAC 
                      Y    D    P    L    N    G    E    V    D    G    V    T    S    D    D    E    D    E    Y    I    E    E    T    D    A    L    G    N    T      609
        1741    TATGATCCCCTAAACGGTGAAGTCGATGGCGTGACATCCGATGATGAAGATGAGTACATTGAAGAAACCGATGCTTTAGGGAATACA 
                      I    K    K    R    I    I    E    H    S    D    V    E    N    E    N    V    K    D    N    E    E    L    Q    E    I    D    N    V    S      638
        1828    ATCAAAAAAAGGATCATAGAACATTCTGATGTTGAAAACGAGAATGTAAAAGATAATGAAGAACTGCAAGAAATCGACAATGTGAGC 
                      L    D    E    P    K    I    N    V    E    D    Q    L    E    T    S    S    D    E    E    D    V    I    P    A    P    P    I    N    Y      667
        1915    CTTGACGAACCAAAGATCAATGTTGAAGATCAACTAGAAACATCATCTGATGAGGAAGATGTTATACCAGCTCCACCTATCAATTAT 
                      A    R    S    F    S    T    V    P    A    T    P    L    T    Y    S    L    R    S    V    I    V    H    Y    G    T    H    N    Y    G      696
        2002    GCTAGGTCATTTTCCACAGTTCCAGCCACTCCATTGACATATTCATTGCGCTCTGTCATTGTTCACTACGGTACCCATAATTATGGT 
                      H    Y    I    A    F    R    K    Y    R    G    C    W    W    R    I    S    D    E    T    V    Y    V    V    D    E    A    E    V    L      725
        2089    CATTACATTGCATTTAGAAAATACAGGGGTTGTTGGTGGAGAATATCTGATGAGACTGTGTACGTTGTGGACGAAGCTGAAGTCCTT 
                      S    T    P    G    V    F    M    L    F    Y    E    Y    D    F    D    E    E    T    G    K    M    K    D    D    L    E    A    I    Q      754
        2176    TCAACACCCGGTGTATTTATGTTATTTTACGAATATGACTTTGATGAAGAAACTGGGAAGATGAAGGATGATTTGGAAGCTATTCAG 
                      S    N    N    E    E    D    D    E    K    E    Q    E    Q    K    G    V    Q    E    P    K    E    S    Q    E    Q    G    E    G    E      783
        2263    AGTAATAATGAAGAAGATGATGAAAAAGAGCAGGAGCAAAAAGGAGTCCAGGAGCCAAAGGAAAGCCAAGAGCAAGGAGAAGGTGAA 
                      E    Q    E    E    G    Q    E    Q    M    K    F    E    R    T    E    D    H    R    D    I    S    G    K    D    V    N    *                  809
        2350    GAGCAAGAGGAAGGTCAAGAGCAGATGAAGTTCGAGAGAACAGAAGACCATAGAGATATTTCTGGTAAAGATGTAAACTAA
A
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correspond to 710 U of the purified UBPDQL and 1650 U
of UBPD2QL, respectively.
We would like to stress that the presence of 6xHis at the C-
end of UBP1 analogues may greatly facilitate purification
of the recombinant protein containing ubiquitin tagged at
its N-end with 6 histidine residues. We propose a three
steps procedure: 1) purification of the fusion protein on a
Ni-NTA column followed by dialysis; 2) digestion of the
purified fusion with a UBP1 analogue, and 3) chromatog-
raphy of the digestion mixture on the same column. The
protein 6xHisUBI::S, used for activity determination, was
treated in this way (Figure 7). SDS-PAGE image analysis
showed that this simple procedure leads to an almost pure
peptide because of the undigested fusion protein. His-
tagged ubiquitin and protease bind to the Ni-NTA column
while after the digestion of the fusion, the liberated pro-
tein flows out of the Ni-NTA column. Such an approach
greatly simplifies the purification of the fusion proteins
and the limited number of purification stages greatly
enhances the efficiency of the whole process.
It should be noted that a solution similar to ours, pro-
duced artificially as a result of UBP1 gene truncation [6],
was observed by Schmitz et al. [7], who discovered two
forms of UBP1 in the yeast cells, the anchored and the sol-
uble one.
Conclusion
Our results show that an efficient expression of the
unmodified yeast UBP1 protease gene in E. coli in the pre-
sented expression system is impossible. The most impor-
tant change to be introduced into the UBP1 gene is the
Q754L mutation leading to the replacement of glutamine
by leucine at position 754 in the aa sequence in the yeast
UBP1. The removal of the transmembrane N-end region
Dependence of the expression level of the shorter analogue of UBP1, UBP1D2QL, on the time after IPTG induction as  revealed by SDS electrophoresis in 12% polyacrylamide gel Figure 2
Dependence of the expression level of the shorter analogue of UBP1, UBP1D2QL, on the time after IPTG 
induction as revealed by SDS electrophoresis in 12% polyacrylamide gel. E. coli BL21 (DE3) cells transformed by the 
plasmid pT7UPD2QL were cultured at 25°C in LB, and induced by the addition of IPTG to the final concentration of 1 mM. 
Aliquots of cultures were taken at: 1 – 0 min, 2 – 30 min, 3 – 60 min, 4 – 90 min, 5 – 120 min, 6 – 150 min after induction.
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of UBP1 improves the level of expression of a properly
truncated gene. Both of these changes in the gene decrease
the time needed for bacteria cultivation.
We have shown that using protease analogues, tagged at
the C-end by 6xHis, for cleaving fusion proteins contain-
ing N-end His-tagged ubiqutin of the type 6xHisUBI::pro-
tein facilitates purification of the protein present in the
hybrid to a great extent.
The high expression level in E. coli of our UBP1 analogues
allows the use of ubiquitin::protein fusion in large scale
production of recombinant proteins.
Methods
Bacterial Strains, Plasmids, Enzymes, and Reagents
Saccharomyces cerevisiae, strain W303, was used as a source
of the DNA for PCR amplification. The E. coli DH5α ,
NM522 strains were used for transformations to obtain
Expression level of the UBP1 analogues as revealed by SDS electrophoresis in 12% polyacrylamide gel Figure 3
Expression level of the UBP1 analogues as revealed by SDS electrophoresis in 12% polyacrylamide gel. 1 and 2 – 
lysates of E. coli BLD3(DE3) bacteria transformed with pT7UPD2QL, not induced and induced with IPTG from cultures main-
tained in 100 ml LB media, respectively; 3 – supernatant after sonication of the bacteria culture performed in the fermenter; 4 
and 5 – lysates of E. coli BLD3 bacteria transformed with pT7UPDQL, cultured, not induced and induced with IPTG, 
respectively.
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Activity of UBPD2QL protease in bacterial cells, SDS electrophoresis in 12% polyacrylamide of bacterial lysates Figure 4
Activity of UBPD2QL protease in bacterial cells, SDS electrophoresis in 12% polyacrylamide of bacterial 
lysates. 1 – molecular mass marker (kDa); 2 and 3 – lysates of E. coli BLD3 (DE3) bacteria transformed with pT7UPDQL2, cul-
tured, induced and not induced with IPTG, respectively. The ubiquitin band is marked with an arrow.
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Expression level of UBP1 analogue with Q754L mutation (UBPQL) as revealed by SDS electrophoresis in 12% polyacrylamide  gel Figure 5
Expression level of UBP1 analogue with Q754L mutation (UBPQL) as revealed by SDS electrophoresis in 12% 
polyacrylamide gel. 1 – molecular mass marker (kDa); 2 and 3 – lysates E. coli BLD21(DE3) bacteria transformed with 
pT7UPQL, cultured, not induced and induced with IPTG, respectively. The UBPQL protease and ubiquitin bands are marked 
with arrows.
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recombinant plasmids. The E. coli BLD21 (DE3) strain
was applied to achieve expression of the His6-tagged ana-
logues of the UBP1 protease. The plasmid pT7RS (Gen-
Bank Accession No. AY923866), containing ArgU tRNA
(UCU) gene and the transcription terminator of phage T7
RNA polymerase, was used for the construction of the
expression system. The E. coli BLD21 (DE3) cells with the
pT7RS plasmid derivatives were cultured aerobically at
25°C or 37°C in LB medium supplemented with 50 µg/
ml ampicilin. Restriction, modification enzymes were
purchased from Amersham Pharmacia Biotech. The rea-
gents for PCR and Ni-NTA Superflow columns were
obtained from Qiagen. IPTG, agarose, polyacrylamide
and the reagents for protein purification were purchased
from Sigma-Aldrich ChemieGmbH, Steinheim, Germany.
For site-directed mutagenesis the Stratagene kit was used
(Cat. No. 200518-5). We used the GelScan v. 1.45 soft-
ware package for the densitometric analysis of the electro-
phoretic image.
The buffers used for the purification of UBP1 analogues
were: buffer A (50 mM buffer phos. pH 8.0; 0.3 M NaCl;
10 mM imidazol; 10 mM 2-β -mercapthoethanol; 10%
glicerol; 0,1% Triton), buffer B (50 mM phosphate buffer,
pH 8.0; 0.3 M NaCl; 40 mM imidazol; 10 mM 2-β -mer-
capthoethanol; 10% glicerol; 0,1% Triton) and buffer C
(50 mM phosphate buffer pH 8.0; 0,3 M NaCl; 300 mM
imidazol; 10 mM 2-β -mercapthoethanol; 10% glicerol;
0,1% Triton).
Plasmid construction
To facilitate subsequent purification of the UBP1 variants
or fusion proteins, the pT7CH, pT7NH, pT7U and
pT7NHU plasmids were constructed. The first one con-
tains in the 3' polilinker part the 6 histidines coding
sequences followed by a TAA stop triplet. The second one
was constructed for the addition of 6 histidines tags to the
N-ends of hybrid proteins. It contains 6 histidines coding
sequences following an ATG triplet.
Activity of the UBP1 analogues, UBPDQL and UBPD2QL, as revealed by SDS electrophoresis in 12% polyacrylamide gel Figure 6
Activity of the UBP1 analogues, UBPDQL and UBPD2QL, as revealed by SDS electrophoresis in 12% polyacr-
ylamide gel. 1 and 2 – the substrate 6xHisUBI::S digested with UBPDQL and UBPD2QL, respectively; 3 – the undigested sub-
strate, 6xHisUBI::S; 4 – molecular mass marker (kDa); 5 and 6 – the substrate UBI::K digested with UBPD2QL and UBPDQL; 7 
– the undigested substrate, UBI::K.
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The pT7CH was obtained by inserting a short double
stranded DNA fragment formed by two synthetic oligonu-
cleotides, HIST7G and HIST7D (Table 1), into the pT7RS
plasmid digested with EcoRI and HindIII restriction nucle-
ases. Similarly, the pT7NH was constructed by inserting a
Digestion of the 6xHisUBI::S fusion with UBPD2QL and purification of peptide S on an Ni-NTA column. SDS electrophoresis  in 12% polyacrylamide gel Figure 7
Digestion of the 6xHisUBI::S fusion with UBPD2QL and purification of peptide S on an Ni-NTA column. SDS 
electrophoresis in 12% polyacrylamide gel. 1 – molecular mass marker (kDa), 2 – 6HisUbi::S purified in a chromatogra-
phy column containing Ni-NTA medium, 3 – 6xHisUBI::S digested with protease UBPD2QL, 4 – S protein purified in a chroma-
tography column filled with Ni-NTA medium.
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double stranded DNA fragment formed by 6HisG  and
6HisD  oligonucleotides (Table 1) into pT7RS digested
with NdeI and EcoRI.
The pT7U plasmid contains a nucleotide sequence encod-
ing modified yeast ubiqutin with the SacII restriction
nuclease recognition sequence near the 3' end of the
sequence, facilitating construction of different hybrid
genes. Primers UB1G and UBID2 (Table 1) were used to
amplify and modify the ubiquitin gene. The plasmid was
used to express the fusion proteins: ubiquitin::modified
UBP1.
The pT7NHU plasmid contains a synthetic nucleotide
sequence encoding ubiquitin with the codons used most
frequently in the E. coli genome, inserted into the pT7NH
plasmid. This plasmid was used to express a hybrid gene
for the synthesis of the substrate for the determination of
UBP1 activity.
The  UBP1  protease gene was obtained using PCR. For
amplification, the UBP1G and UBP1D primers were used
(Table 1). The oligonucleotides contained recognition
sites for the restriction endonucleases SacII and BamHI,
respectively. The PCR was performed in a 50 µl reaction
volume with a buffer containing 50 mM KCl, 1.75 mM
MgCl2, 0.02 mM of each dNTP, 10 mM Tris-HCl (pH 8.9),
100 pM of each primer, the enzyme mixture of Taq and
Pwo DNA polymerases (Expand Long Template PCR Sys-
tem, Roche) and 100 ng of total DNA of S. cerevisiae as a
template for 30 cycles using Eppendorf 5330 thermocy-
cler. Each cycle consisted of 15 sec at 94°C, 15 sec at
56°C, and 2 min at 72°C. The amplified 2430-bp-long
DNA fragment was isolated by 1% agarose gel electro-
Table 1: Primers for the construction of pT7RS and UBP1 derivatives
Primersa Sequencesb Restriction site
HIST7G 5' AATTCGATATCGTCGACGGATCCCATCATCACCATCACCATTAAAAT 3' EcoRI
HIST7D 5' AGCTATTTTAATGGTGATGGTGATGATGGGATCCGTCGACGATATCG 3' BamHI, SalI, EcoRV,
6HisG 5' TATGGCACATCATCACCATCACCACTCTGGTTCTG 3' NdeI
6HisD 5' AATTCAGAACCAGAGTGGTGATGGTGATGATGTGCCA 3' EcoRI
UB1G 5' GGGGAATTCATATGCAGATTTTCGTCAAAACTTTG 3' EcoRI and NdeI
UBID2 5' GGGGATCCTTAATGCTCTTCACCACCGCGGAGTCTTAAG 3' BamHI and SacII
UBP1G 5' AGACTCCGCGGTGGTGATTTGTTTATTGAAAGCAAGATA 3' SacII
UBP1D 5' GGGGATCCTTAGTTTACATCTTTACCAGAAATA 3' BamHI
UBP1MG 5'GGCATAGTAGTATTTTTTTACCGCGGTGGTGACCATCTAAACTACATTGT 3' SacII
UBP1MD 5'ACAATGTAGTTTAGATGGTCACCACCGCGGTAAAAAAATACTACTATGCC 3' SacII
SkrutG 5'AAAACCGCGGTGGTTTCATTGCTGGTTTA 3' SacII
SkrutD 5'GGAAGAATTCTTGCGCGTCCTC 3' EcoRI
UBP1GC 5'-GATTTGGAAGCTATTCAGAGTAATAATGAAG-3'
UBP1DC 5'-CTTCATTATTACTCTGAATAGCTTCCAAATC-3'
KalaG 5'-GATCCAGGCGATAAAGACGGTGATGGCTATATTTCTGCTGCTGAAGCTATGGCTTA-3' BamHI
KalaD 5'-AGCTTAAGCCATAGCTTCAGCAGCAGAAATATAGCCATCACCGTCTTTATCGCCTG-3' HindIII
a The names of primers contain the letters: G – sense or D – antisense.
b The restriction sites are underlined or overlined. The histidine and leucine codons are in bold face.
Table 2: Plasmids and genes used to construct vectors of the pT7RS derivatives
Vectors Gene cloned Result ing 
vectors
Expression 
products
Name of the protein 
used in the text
pT7SR Ubiquitin pT7U Ubiquitin UBI
pT7U K pT7UK UBI::K UBI::K
UBP1 pT7UP UBI::UBP1 UBP1
pT7CH UBI::UBP1 with Q754L mutation pT7UPQL UBI::UBPQL::6xHis UBPQL
UBI::UBP1(55-809) without Q754L mutation pT7UPD UBI::UBPD::6xHis UBPD
UBI::UBP1(55-809) with Q754L mutation pT7UPDQL UBI::UBPDQL::6xHis UBPDQL
pT7CH UBI::UBP1(99-809) with Q754L mutation pT7UPD2QL UBI::UBPD2QL::6xHis UBPD2QL
pT7NH Ubiquitin pT7NHU 6xHis::UBI 6xHisUBI
pT7NHU S pT7NHUS 6xHis::UBI::S 6xHisUBI::SMicrobial Cell Factories 2005, 4:17 http://www.microbialcellfactories.com/content/4/1/17
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phoresis using Gel-Out kit (Kucharczyk T. E. Co, Warsaw),
digested with BamHI and SacII restriction nucleases, puri-
fied and ligated to BamHI and SacII digested pT7U vector.
Ligation products were transformed into the NM522 E.
coli strain. Plasmid DNA was isolated using the alkaline
method [8]. Next, the 2430 bp UBP1 gene was excised
from the recombinant plasmid using the restriction
enzymes NdeI and BamHI, and the DNA fragment encod-
ing hybrid gene ubiquitin::UBP1  was recloned into the
pT7CH plasmid at the NdeI and BamHI sites. In this way
the pT7UPQL vector was obtained (Table 2).
UBP1 variants
PCR was used to remove the transmembrane domain
from the UBP1 gene. Two variants were obtained. In the
first variant, a 162 bp fragment was removed from the 5'
part of the coding sequence. For this purpose, site-directed
mutagenesis was used with the primers UBP1MG and
UBP1MD (Table 1). The shortened gene was modified by
the addition of '5-GGTGGT-3', the sequence encoding
Gly-Gly, the C-end amino-acids of ubiquitin, and the
SacII nuclease recognition sequence. We called this
mutein UBPDQL (Figure 1).
The second, shorter variant of UBP1 was prepared by PCR
using SkrutG and SkrutD primers (Table 1). In this way an
additional 132 bp long DNA fragment was removed. The
new variant of the protease consisted of 711 aa (Figure 1).
We named this protease variant UBPD2QL. The two
shorter variants of the UBP1 gene were inserted into the
pT7UCH expression plasmid. The obtained plasmids
were designated pT7UPDQL and pT7UPD2QL, and used
for the synthesis of UBPDQL and UBPD2QL proteases,
respectively (Table 2).
Both variants of the modified gene contain the same
mutation leading to CAG to CTG codon change (gln →
leu, Figure 1A), which appeared after the first
amplification of the UBP1  gene. This mutation was
removed using the site-directed kit with the primers
UBP1GC and UBP1DC (Table 1).
To circumvent the codon usage problem [9], the UBP1
protease gene was modified through the exchange of cer-
tain argining codons (AGA or AGG for CGT or CGC) and
leucine codons (TTA for CTG). Stratagene mutagenesis kit
with turbo-polymerase was used for site-directed mutagen-
esis. In this way the following replacements were made:
arginine's codons in positions 96, 334, 425, 476, 482,
487, 613, 702, 705, 710, 796 and 801, and leucine codons
in positions 354, 356, 358, 367, 369, 372, 373, 469 and
470 of the UBP1 amino-acid sequence (Figure 1A).
Determination of the activity of the UBI::UBP1 protease 
variants
In order to determine the protease activity of the UBP1
analogues, two hybrid proteins were obtained. To obtain
the first one, the 354 bp long DNA fragment, encoding the
C-terminal end of the UBP1 protease named S, was cloned
into the pT7NHU plasmid (Figure 1A, B). The second one
consists of yeast ubiquitin followed by:
AspProGlyAspLysAspGlyAspGlyTyrIleSerAlaAlaGluAla-
MetAla-, a peptide analogous to the IIId calcium-binding
loop of calmodulin [10]. The sequence encoding this
fusion peptide was obtained by ligation of the yeast ubiq-
uitin gene with synthetic oligonucleotides: KalaG and
KalaD (Table 1), and cloned into pT7U. Both plasmids
were used to transform E. coli BLD21 (DE3) cells with the
aim of obtaining the hybrid proteins 6xHisUBI::S and
UBI::K (Table 2). Both fusion proteins were soluble dur-
ing the synthesis in E. coli. The 6xHisUBI::S was purified
by Ni-NTA affinity chromatographs. The UBI::K protein
was purified by ion exchange chromatography on a col-
umn of DEAE-Sepharose Fast Flow (Pharmacia LKB), fol-
lowed by NiCl affinity chromatography using Chelating
Sepharose Fast Flow (Pharmacia LKB). In both cases, the
expression level and purity of the hybrid proteins were
high enough (data not shown) to be used for activity
determination. The reactions were performed in a volume
of 50 µl at 37°C for 30 min. in a buffer of the following
composition: 20 mM phosphate pH 7.5, 2 mM DDT, 1
mM EDTA. 4 µg (380 pM) of the substrate UBI::K or 2 µg
(87 pM) of 6xHisUBI::S were digested with 1.5 µg (18.2
pM) of the protease variants. The digestion reactions were
stopped by heating at 100°C for 3 min. in the presence of
SDS, and the digestion products were analyzed using SDS-
PAGE (12%) (Figure 6). The unit (U) of enzyme activity is
defined as the amount (of the enzyme) which will cata-
lyze the transformation of 1 micromole of the substrate
per minute under standard conditions.
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UBP – ubiquitin-specific protease (Ubp)
SDS – sodium dodecyl sulfate
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